Eton Pharmaceuticals has licensed U.S. rights to ASN-001, a late-stage topical gel targeting moderate infantile hemangiomas, a condition currently treated off-label with ophthalmic timolol. ASN-001 complements Eton's existing oral solution HEMANGEOL, potentially covering the full spectrum of infantile hemangioma patients. Phase II/III trials showed significant efficacy, with up to 56% elimination or near-elimination at 24 weeks. Eton plans to submit a New Drug Application in the second half of 2027, aiming for FDA approval and launch in 2028, targeting an estimated 20,000 to 30,000 patients annually and expanding its pediatric dermatology portfolio.
An unauthorized party exploited the SingularityNET bridge infrastructure, withdrawing about $1.56 million worth of FET tokens. Fetch.ai confirmed its own contracts remain secure and unaffected, but paused AGIX-to-FET conversions and the Ethereum-side...
Hyperliquid, a decentralized perpetuals exchange, reached an all-time high open interest of $8.1 billion on September 20, 2026, representing about 10.9% of the global perpetual futures market. This milestone was driven by the launch of tokenized trad...
Bitcoin recovered from $75,000 to nearly $82,000 last week, driven by institutional demand and short position liquidations. However, the price hit strong resistance between $81,500 and $82,300, limiting further gains. Geopolitical tensions in the Mid...
Zama (ZAMA) surged 27% to a new all-time high of $0.092 before slightly retracing to around $0.086, driven by strong buying pressure and increased market activity. The altcoin's market cap surpassed $200 million, with daily trading volume rising 149%...
Paradex, a decentralized derivatives exchange on Starknet, executed a record $15.76 million ETH options trade with a premium cost lower than centralized exchange Deribit. This milestone followed Paradex's integration of Paradigm's RFQ liquidity netwo...
